1-3 of 3
Markus Sieber
Close
Sort by
Journal Articles

Cologne High-Dose Sequential Chemotherapy in Relapsed and Refractory Hodgkin Lymphoma - Results of a Large Multicenter Study of the German Hodgkin Lymphoma Study Group (GHSG).

Andreas Josting, MD, Christian Rudolph, MD, Markus Mapara, MD, Jan-Peter Glossmann, MD, Markus Sieber, MD, Hartmut H. Kirchner, MD, Bernd Dörken, MD, Dieter K. Hossfeld, MD, Jens Kisro, MD, Bernd Metzner, MD, Wolfgang E. Berdel, MD, Volker Diehl, MD, Andreas Engert, MD
Journal: Blood
Blood (2004) 104 (11): 309.
https://doi.org/10.1182/blood.V104.11.309.309
Published: 2004
Journal Articles

Treatment of relapsed CD20 + Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group

Clinical Trials & Observations
Ute Rehwald, Holger Schulz, Marcel Reiser, Markus Sieber, Jan Oliver Staak, Franck Morschhauser, Christoph Driessen, Thomas Rüdiger, Konrad Müller-Hermelink, Volker Diehl, Andreas Engert
Journal: Blood
Blood (2003) 101 (2): 420–424.
https://doi.org/10.1182/blood.V101.2.420
Published: 2003
Journal Articles

Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group

Clinical Trials & Observations
Andreas Josting, Ulrich Rueffer, Jeremy Franklin, Markus Sieber, Volker Diehl, Andreas Engert
Journal: Blood
Blood (2000) 96 (4): 1280–1286.
https://doi.org/10.1182/blood.V96.4.1280
Published: 2000